Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (NASDAQ:BEAM), sold 6,198 shares for around $216,933 at a weighted average price of $35.00 per share on Jan. 22, 2026. This represented 15.11% of her direct post-transaction holdings, reducing ownership from 41,011 to 34,813 shares. Beam Therapeutics focuses on gene editing therapies to treat diseases like leukemia and sickle cell anemia. The company announced its 2026 strategic priorities, aiming to advance genetic medicines beyond clinical trials. With FDA support for leading candidates, Beam Therapeutics plans to gain approval for new treatments by year-end.

Read more at NASDAQ.: Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933